| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8829005 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(5 years from now) | |
| US9993471 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(5 years from now) | |
| US9750684 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Mar, 2030
(5 years from now) | |
|
US8829005 (Pediatric) | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Sep, 2030
(6 years from now) | |
| US9254286 | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Jul, 2032
(8 years from now) | |
|
US9254286 (Pediatric) | HARROW EYE | Ophthalmic formulations of cetirizine and methods of use |
Jan, 2033
(8 years from now) | |
Zerviate is owned by Harrow Eye.
Zerviate contains Cetirizine Hydrochloride.
Zerviate has a total of 6 drug patents out of which 0 drug patents have expired.
Zerviate was authorised for market use on 30 May, 2017.
Zerviate is available in solution/drops;ophthalmic dosage forms.
Zerviate can be used as treatment of ocular itching associated with allergic conjunctivitis.
The generics of Zerviate are possible to be released after 09 January, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 30, 2020 |
| Pediatric Exclusivity(PED) | Nov 30, 2020 |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2017
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
ZERVIATE family patents
